Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
1. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991;165:1168-1176.
2. Foxman B, Marsh JV, Gillespie B, et al. Frequency and response to vaginal symptoms among white and African American women: Results of a random digit dialing survey. J Womens Health. 1998;7:1167-1174.
4. Sobel JD. Vulvovaginitis in healthy women. Compr Ther. 1999;25:335-346.
5. Sobel JD. Pathogenesis of recurrent vulvovaginal candidiasis. Curr Inf Dis Rep. 2002;4:514-519.
6. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007; 34:864-869.
7. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353:1899-1911.
8. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol. 1993;169:450-454.
9. Hay P. Recurrent bacterial vaginosis. Curr Infect Dis Rep. 2000;2:506-512.
10. Schwebke J, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196:517.e1-6.
11. Peipert J, Montagno AB, Cooper AS, et al. Bacterial vaginosis as a risk factor for upper genital tract infection. Am J Obstet Gynecol. 1997;177:1184-1187.
12. British Association for Sexual Health and HIV. UK National guideline for the management of bacterial vaginosis. 2012. http://www.bashh.org (last accessed 21 October 2016).
13. Taha TE, Hoover DR, Dallabetta GA, et al. Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS. 1998;12:1699-1706.
14. Vutyavanich T, Pongsuthirak P, Vannareumol P, et al. A randomized double-blind trial of tinidazole treatment of the sexual partners of females with bacterial vaginosis. Obstet Gynecol. 1993;82:550-554.
15. Leitich H, Bodner-Adler B, Brunbauer M, et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am J Obstet Gynecol. 2003;189;139-147.
16. Hauth JC, Goldenberg RL, Andrews WW, et al. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732-1736.
17. Kigozi GG, Brahmbhatt H, Wabwire-Mangen F, et al. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2003;189:1398-1400.
18. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. N Engl J Med. 2001;345:487-493.
19. Anderson MR, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291:1368-1379.
20. Centers for Disease Control and Prevention, Division of Parasitic Diseases. Trichomonas Infection. 2004.
21. Krieger JN. Urologic aspects of trichomoniasis. Invest Urol. 1981;18:411-417.
22. Sena AC, Miller WC, Hobbs MM, et al. Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis. 2007;44:13-22.
23. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64:1-137.
24. British Association for Sexual Health and HIV. United Kingdom national guideline on the management of trichomonas vaginalis 2014. March 2014. http://www.bashh.org (last accessed 21 October 2016).
25. Sobel JD. Vaginal infections in adult women. Med Clin North Am. 1990;74:1573-1602.
26. Ferris DG, Nyirjesy P, Sobel JD, et al. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99:419-425.
27. De Leon EM, Jacober SJ, Sobel JD, et al. Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes. BMC Infect Dis. 2002;2:1.
28. Eckert LO, Hawes SE, Stevens CE, et al. Vulvovaginal candidiasis: Clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998;92:757-765.
29. Spinillo A, Pizzoli G, Colonna L, et al. Epidemiologic characteristics of women with idiopathic recurrent vulvovaginal candidiasis. Obstet Gynecol. 1993;81:721-727.
30. Spinillo A, Capuzzo E, Gulminetti R, et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997;176:138-141.
31. Sobel JD. Vaginitis. N Engl J Med. 1997;337:1896-1903.
32. Verstraelen H, Verhelst R, Vaneechoutte M, et al. Group A streptococcal vaginitis: an unrecognized cause of vaginal symptoms in adult women. Arch Gynecol Obstet. 2011;284:95-98.
33. Yirenya-Tawiah D, Amoah C, Apea-Kubi KA, et al. A survey of female genital schistosomiasis of the lower reproductive tract in the Volta basin of Ghana. Ghana Med J. 2011;45:16-21.
34. Foda AA, El-Malky MM. Prevalence of genital tract infection with Entamoeba gingivalis among copper T 380A intrauterine device users in Egypt. Contraception. 2012;85:108-112.
35. McGowin CL, Anderson-Smits C. Mycoplasma genitalium: an emerging cause of sexually transmitted disease in women. PLoS Pathog. 2011; 7:e1001324.
36. Rodrigues AC, Teixeira R, Teixeira T, et al. Impact of pelvic radiotherapy on female sexuality. Arch Gynecol Obstet. 2012;285:505-514.
37. Baessler K, Hewson AD, Tunn R, et al. Severe mesh complications following intravaginal slingplasty. Obstet Gynecol. 2005;106:713-716.
38. Stott D, Zakaria M. The transcervical expulsion of a large fibroid. BMJ Case Reports. BMJ Case Rep. 2012;2012:bcr0120125523.
39. de la Poza G, López-Sanroman A, Taxonera C, et al. Genital fistulas in female Crohn's disease patients: clinical characteristics and response to therapy. J Crohns Colitis. 2012;6:276-280.
40. Sanfilippo JS, Wakim NG. Bleeding and vulvovaginitis in the pediatric age group. Clin Obstet Gynecol. 1987;30:653-661.
41. McGreal S, Wood P. Recurrent vaginal discharge in children. J Pediatr Adolesc Gynecol. 2013;26:205-208.
42. Jaquiery A, Stylianopoulos A, Hogg G, et al. Vulvovaginitis: clinical features, aetiology, and microbiology of the genital tract. Arch Dis Child. 1999;81:64-67.
43. Striegel AM, Myers JB, Sorensen MD, et al. Vaginal discharge and bleeding in girls younger than 6 years. J Urol. 2006;176:2632-2635.
44. Simon DA, Berry S, Brannian J, et al. Recurrent, purulent vaginal discharge associated with longstanding presence of a foreign body and vaginal stenosis. J Pediatr Adolesc Gynecol. 2003;16:361-363.
45. Merkley K. Vulvovaginitis and vaginal discharge in the pediatric patient. J Emerg Nurs. 2005;31:400-402.
46. Singh RH, Zenilman JM, Brown KM, et al. The role of physical examination in diagnosing common causes of vaginitis: a prospective study. Sex Transm Infect. 2013;89:185-190.
47. Ou YC, Huang HY, Huang CC, et al. Primary fallopian tube carcinoma: clinicopathological analysis of 12 cases. Taiwan J Obstet Gynecol. 2011;50:141-144.
48. Cao XX, Li J, Zhang W, et al. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. Ann Hematol. 2014;93:1001-1005.
49. Bull L, Knowles A, Ogden S, et al. Primary cervical lymphoma: a rare presentation to a genitourinary medicine clinic. Int J STD AIDS. 2013;24:587-589.
50. Klebanoff MA, Schwebke JR, Zhang J, et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol. 2004;104:267-272.
51. Bradshaw CS, Morton AN, Garland SM, et al. Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis. Obstet Gynecol. 2005;106:105-114.
52. Smart S, Singal A, Mindel A. Social and sexual risk factors for bacterial vaginosis. Sex Transm Infect. 2004;80:58-62.
53. Beigi RH, Wiesenfeld HC, Hillier SL, et al. Factors associated with absence of H2O2-producing Lactobacillus among women with bacterial vaginosis. J Infect Dis. 2005;191:924-929.
54. Mittal V, Jain A, Pradeep Y. Development of modified diagnostic criteria for bacterial vaginosis at peripheral health centres in developing countries. J Infect Dev Ctries. 2012;6:373-377.
55. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14-22.
56. Simoes JA, Discacciati MG, Brolazo EM, et al. Clinical diagnosis of bacterial vaginosis. Int J Gynaecol Obstet. 2006;94:28-32.
57. Cartwright CP, Lembke BD, Ramachandran K, et al. Comparison of nucleic acid amplification assays with BD affirm VPIII for diagnosis of vaginitis in symptomatic women. J Clin Microbiol. 2013;51:3694-3699.
58. Petrin D, Delgaty K, Bhatt R, et al. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11:300-317.
59. DeMeo LR, Draper DL, McGregor JA, et al. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol. 1996;174:1339-1342.
60. Gaydos CA, Hsieh YH, Barnes M, et al. Trichomonas vaginalis infection in women who submit self-obtained vaginal samples after internet recruitment. Sex Transm Dis. 2011;38:828-832.
61. Sellors J, Howard M, Pickard L, et al. Chlamydial cervicitis: testing the practice guidelines for presumptive diagnosis. CMAJ. 1998;158:41-46.
62. Geisler WM, Chow JM, Schachter J, et al. Pelvic examination findings and Chlamydia trachomatis infection in asymptomatic young women screened with a nucleic acid amplification test. Sex Transm Dis. 2007;34:335-338.
63. Centers for Disease Control and Prevention. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae. March 2014. http://www.cdc.gov (last accessed 21 October 2016).
64. Stenchever MA, Droegemueller W, Herbst AL, et al. Comprehensive gynecology. 4th ed. St. Louis, Missouri: Mosby; 2006; 655-656.
65. Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002; 35(Suppl 2):S173-S182.
66. Pretorius R, Semrad N, Watring W, et al. Presentation of cervical cancer. Gynecol Oncol. 1991;42:48-53.
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台